Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database.

ABSTRACT:

Introduction

Gabapentin and pregabalin are widely prescribed to elderly people, but data on their pharmacokinetics, safety, and efficacy in this population are scarce. Neurological adverse effects are common. Atrial fibrillation (AF) associated with their use has been described in several case reports and case series, but the incidence is unknown.

Objective

The aim of this study was to assess the association between exposure to gabapentin or pregabalin and AF in the elderly.

Methods

Patients ≥ 65 years of age starting treatment with either gabapentin or pregabalin between January 1 and March 31, 2015, free of cardiovascular disease, and who did not receive the alternate study medications were studied. They were compared with patients who initiated treatment with an an

SUBMITTER: Ortiz de Landaluce L 

PROVIDER: S-EPMC6223696 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature